6/24
07:26 am
dsnky
Daiichi Sankyo peripheral T-cell lymphoma therapy approved in Japan [Yahoo! Finance]
Low
Report
Daiichi Sankyo peripheral T-cell lymphoma therapy approved in Japan [Yahoo! Finance]
6/12
03:39 am
dsnky
Daiichi Sankyo Is Riding The ADC Revolution To Billions In Future Revenue [Seeking Alpha]
Low
Report
Daiichi Sankyo Is Riding The ADC Revolution To Billions In Future Revenue [Seeking Alpha]
6/5
10:12 am
dsnky
Pink Fund Announces Gissoo DeCotiis As New Board Member [Yahoo! Finance]
Low
Report
Pink Fund Announces Gissoo DeCotiis As New Board Member [Yahoo! Finance]
6/2
08:20 am
dsnky
AstraZeneca's Lung, Breast Cancer Drugs Markedly Slow Disease [BNN Bloomberg (Canada)]
Low
Report
AstraZeneca's Lung, Breast Cancer Drugs Markedly Slow Disease [BNN Bloomberg (Canada)]
6/2
08:00 am
dsnky
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
Low
Report
ENHERTU® Demonstrated a Median Progression-Free Survival of 13.2 Months in HR Positive, HER2 Low and HER2 Ultralow Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy
5/29
03:15 am
dsnky
New subgroup analyses of CLEAR Outcomes data showed bempedoic acid reduced the risk of major adverse cardiovascular events across various patient groups [Yahoo! Finance]
Low
Report
New subgroup analyses of CLEAR Outcomes data showed bempedoic acid reduced the risk of major adverse cardiovascular events across various patient groups [Yahoo! Finance]
5/27
03:19 am
dsnky
Multidisciplinary Think Tank proposes recommendations to improve holistic cardiovascular care in Europe [Yahoo! Finance]
Low
Report
Multidisciplinary Think Tank proposes recommendations to improve holistic cardiovascular care in Europe [Yahoo! Finance]
5/24
08:40 am
dsnky
Debbie's Dream Foundation Partners with KIBOUNOKAI to Empower the Japanese Community in Stomach Cancer Awareness and Education [Yahoo! Finance]
Low
Report
Debbie's Dream Foundation Partners with KIBOUNOKAI to Empower the Japanese Community in Stomach Cancer Awareness and Education [Yahoo! Finance]
5/22
08:19 am
dsnky
First-in-class cholesterol-lowering treatment NILEMDO®? and its combination with ezetimibe, NUSTENDI®?, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk [Yahoo! Finance]
Low
Report
First-in-class cholesterol-lowering treatment NILEMDO®? and its combination with ezetimibe, NUSTENDI®?, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk [Yahoo! Finance]
5/22
08:00 am
dsnky
First-in-class cholesterol-lowering treatment NILEMDO®? and its combination with ezetimibe, NUSTENDI®?, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk
Low
Report
First-in-class cholesterol-lowering treatment NILEMDO®? and its combination with ezetimibe, NUSTENDI®?, approved in Europe to lower LDL cholesterol and reduce cardiovascular risk
5/21
08:23 am
dsnky
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO [Yahoo! Finance]
Low
Report
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO [Yahoo! Finance]
5/21
08:00 am
dsnky
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO
Low
Report
Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO
5/20
09:15 am
dsnky
Perosphere Technologies Adds Dr. Michael Grosso to Advisory Board [Yahoo! Finance]
Low
Report
Perosphere Technologies Adds Dr. Michael Grosso to Advisory Board [Yahoo! Finance]
5/1
01:13 pm
dsnky
Fight Colorectal Cancer Launches ChatCRC: An AI-Powered Chatbot Revolutionizing Colorectal Cancer Support [Yahoo! Finance]
Low
Report
Fight Colorectal Cancer Launches ChatCRC: An AI-Powered Chatbot Revolutionizing Colorectal Cancer Support [Yahoo! Finance]
4/29
07:13 am
dsnky
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow [Yahoo! Finance]
Low
Report
ENHERTU® (fam-trastuzumab deruxtecan-nxki) improved PFS in HER2-low and ultralow [Yahoo! Finance]
4/29
02:00 am
dsnky
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
Low
Report
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
4/25
11:44 am
dsnky
Germany's Scholz pledges support for pharmaceutical industry [Yahoo! Finance]
Low
Report
Germany's Scholz pledges support for pharmaceutical industry [Yahoo! Finance]
4/9
03:35 pm
dsnky
FDA Roundup: April 9, 2024 [Yahoo! Finance]
Low
Report
FDA Roundup: April 9, 2024 [Yahoo! Finance]
4/5
09:52 pm
dsnky
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors [Yahoo! Finance]
Low
Report
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as first tumor-agnostic HER2-directed therapy for previously treated patients with metastatic HER2-positive solid tumors [Yahoo! Finance]
4/5
04:21 pm
dsnky
AstraZeneca's Enhertu granted approval for HER-2 positive tumor-agnostic indications [Seeking Alpha]
Low
Report
AstraZeneca's Enhertu granted approval for HER-2 positive tumor-agnostic indications [Seeking Alpha]
4/5
04:05 am
dsnky
AstraZeneca Says Key Lung Cancer Drug Improved Survival [BNN Bloomberg (Canada)]
Low
Report
AstraZeneca Says Key Lung Cancer Drug Improved Survival [BNN Bloomberg (Canada)]